SG11201907427YA - Engineered transferrin receptor binding polypeptides - Google Patents
Engineered transferrin receptor binding polypeptidesInfo
- Publication number
- SG11201907427YA SG11201907427YA SG11201907427YA SG11201907427YA SG11201907427YA SG 11201907427Y A SG11201907427Y A SG 11201907427YA SG 11201907427Y A SG11201907427Y A SG 11201907427YA SG 11201907427Y A SG11201907427Y A SG 11201907427YA SG 11201907427Y A SG11201907427Y A SG 11201907427YA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutics
- california
- floor
- denali
- south san
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000007238 Transferrin Receptors Human genes 0.000 title abstract 4
- 108010033576 Transferrin Receptors Proteins 0.000 title abstract 4
- 241000237502 Ostreidae Species 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 235000020636 oyster Nutrition 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70582—CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B20/00—Methods specially adapted for identifying library members
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ecology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
PUBLISHEDUNDER THE PATENT COOPERATION TREATY (PCT) 0 0111 °nolo moncill mum° oimIE (10) International Publication Number WO 2018/152326 Al WIPO I PCT (12) INTERNATIONAL APPLICATION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) (51) International Patent Classification: C07K 14/79 (2006.01) A61K 39/00 (2006.01) C07K 14/705 (2006.01) A61K 38/40 (2006.01) (21) International Application Number: PCT/US2018/018371 (22) International Filing Date: 15 February 2018 (15.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 62/460,692 17 February 2017 (17.02.2017) US Published: 62/543,658 10 August 2017 (10.08.2017) US with international search report (Art. 21(3)) 62/583,314 08 November 2017 (08.11.2017) US with sequence listing part of description (Rule 5.2(a)) (71) Applicant: DENALI THERAPEUTICS INC. [US/US]; 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). (72) Inventors: CHEN, Xiaocheng; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Fran- cisco, California 94080 (US). DENNIS, Mark S.; c/o De- nali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). KARIOLIS, Mihalis; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). SILVERMAN, Adam P.; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Fran- cisco, California 94080 (US). SRIVASTAVA, Ankita; c/ o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). WAT- TS, Ryan J.; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). WELLS, Robert C.; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). ZUCHERO, Joy Yu; c/o Denali Therapeutics Inc., 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). (74) Agent: HAO, Joe C. et al.; Kilpatrick Townsend & Stock- ton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street - Suite 2800, Atlanta, Georgia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 1-1 O \" (57) : Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and 0 methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell. (54) Title: ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460692P | 2017-02-17 | 2017-02-17 | |
| US201762543658P | 2017-08-10 | 2017-08-10 | |
| US201762583314P | 2017-11-08 | 2017-11-08 | |
| PCT/US2018/018371 WO2018152326A1 (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907427YA true SG11201907427YA (en) | 2019-09-27 |
Family
ID=61521837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907427YA SG11201907427YA (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US11795232B2 (en) |
| EP (2) | EP4169937A1 (en) |
| JP (2) | JP2020508049A (en) |
| KR (1) | KR20190129868A (en) |
| CN (1) | CN110506055A (en) |
| AU (2) | AU2018221731C1 (en) |
| BR (1) | BR112019016989A2 (en) |
| CA (1) | CA3053375A1 (en) |
| CL (1) | CL2019002307A1 (en) |
| CO (1) | CO2019008873A2 (en) |
| CR (1) | CR20190372A (en) |
| DK (1) | DK3583120T3 (en) |
| EC (1) | ECSP19058592A (en) |
| ES (1) | ES2932759T3 (en) |
| FI (1) | FI3583120T3 (en) |
| HR (1) | HRP20221505T1 (en) |
| HU (1) | HUE060983T2 (en) |
| IL (2) | IL307373A (en) |
| LT (1) | LT3583120T (en) |
| MD (1) | MD3583120T2 (en) |
| MX (2) | MX2019009818A (en) |
| NZ (1) | NZ756763A (en) |
| PE (1) | PE20191551A1 (en) |
| PH (1) | PH12019550147A1 (en) |
| PL (1) | PL3583120T3 (en) |
| PT (1) | PT3583120T (en) |
| RS (1) | RS63818B1 (en) |
| SG (1) | SG11201907427YA (en) |
| SI (1) | SI3583120T1 (en) |
| TW (1) | TWI797106B (en) |
| UA (1) | UA127985C2 (en) |
| WO (1) | WO2018152326A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018152326A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
| KR20200058510A (en) | 2017-10-02 | 2020-05-27 | 데날리 테라퓨틱스 인크. | Fusion protein containing enzyme replacement therapy enzyme |
| JP7397063B2 (en) * | 2018-08-16 | 2023-12-12 | デナリ セラピューティクス インコーポレイテッド | Engineered bispecific proteins |
| AR115998A1 (en) * | 2018-08-22 | 2021-03-25 | Denali Therapeutics Inc | ANTI-HER2 POLYPEPTIDES AND METHODS OF USE OF THE SAME |
| TW202138384A (en) | 2019-12-23 | 2021-10-16 | 美商戴納立製藥公司 | Progranulin variants |
| PE20230036A1 (en) | 2019-12-23 | 2023-01-10 | Denali Therapeutics Inc | PROGRANULIN VARIANTS |
| CN115279790A (en) * | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | anti-TREM 2 antibodies and methods of use thereof |
| TW202128771A (en) | 2020-01-13 | 2021-08-01 | 美商戴納立製藥公司 | Anti-trem2 antibodies and methods of use thereof |
| CN111110834A (en) * | 2020-02-24 | 2020-05-08 | 中国科学院昆明动物研究所 | Use of transferrin or overexpressed transferrin for the preparation of a medicament for the treatment and/or prevention of ulcerative colitis |
| IL302029A (en) | 2020-10-14 | 2023-06-01 | Denali Therapeutics Inc | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| CA3225542A1 (en) | 2021-07-01 | 2023-01-05 | Denali Therapeutics Inc. | Oligonucleotide conjugates targeted to the transferrin receptor |
| WO2023114499A1 (en) | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2024026488A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a modified transferrin receptor locus |
| WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
| US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| WO2024064756A1 (en) * | 2022-09-20 | 2024-03-28 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527527A (en) | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US5260210A (en) | 1989-09-27 | 1993-11-09 | Rubin Lee L | Blood-brain barrier model |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| FR2705194A1 (en) | 1993-05-21 | 1994-11-25 | Transgene Sa | Transgenic animal expressing a transferrin of human origin. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1999000150A2 (en) | 1997-06-27 | 1999-01-07 | Regents Of The University Of California | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MXPA01007170A (en) | 1999-01-15 | 2002-07-30 | Genentech Inc | Polypeptide variants with altered effector function. |
| US7241449B1 (en) | 1999-04-12 | 2007-07-10 | Aventis Pasteur Limited | Transferrin receptor genes of moraxella |
| CA2382812A1 (en) | 1999-08-30 | 2001-03-08 | Joseph Schlessinger | Crystal structures of domains of receptor protein tyrosine kinases and their ligands |
| EP1285272A2 (en) | 2000-02-08 | 2003-02-26 | University of British Columbia | Compositions and methods for screening therapeutic agents |
| JP2001238681A (en) | 2000-03-03 | 2001-09-04 | Japan Science & Technology Corp | Blood-brain barrier reconstruction model by coculture |
| AU2002236499A8 (en) | 2000-11-30 | 2009-12-03 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| BR0210697A (en) | 2001-06-29 | 2004-09-21 | Wyeth Corp | Methods and compositions useful for predicting blood-brain barrier permeation |
| US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
| US20030074141A1 (en) | 2001-10-15 | 2003-04-17 | Camitro Corporation | Meta-models for predicting blood brain barrier penetration based on simple physicochemical descriptors |
| CN1713920A (en) * | 2002-08-30 | 2005-12-28 | 比奥雷克西斯药物公司 | Modified transferrin fusion proteins |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2522700A1 (en) | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| US20050170394A1 (en) | 2004-01-30 | 2005-08-04 | Xenoport, Inc. | GLUT1 transporters expressed in blood brain barrier cells |
| GB0403490D0 (en) | 2004-02-17 | 2004-03-24 | Daniolabs Ltd | Screening methods |
| FR2871162B1 (en) | 2004-06-02 | 2007-06-29 | Univ Paris 7 Denis Diderot | MODIFIED SURFACE MATERIAL, PROCESS FOR PREPARING THE SAME AND USES THEREOF |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
| EP1817410B1 (en) | 2004-11-29 | 2015-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Human blood brain barrier model |
| CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| US8900865B2 (en) | 2005-12-14 | 2014-12-02 | The Invention Science Fund I, Llc | Blood brain barrier device |
| JP5113332B2 (en) | 2005-12-19 | 2013-01-09 | 正美 丹羽 | Blood-brain barrier in vitro model, pathological blood-brain barrier in vitro model, drug screening method using the same, pathological blood-brain barrier function analysis method, etiology analysis method |
| AU2007256639A1 (en) | 2006-06-07 | 2007-12-13 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| US20080044847A1 (en) | 2006-06-23 | 2008-02-21 | Shusta Eric V | Blood-Brain Barrier Model |
| AT503861B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING T-CELL RECEPTORS |
| AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
| AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
| DK2046820T3 (en) | 2006-08-01 | 2011-02-07 | Pieris Ag | Tear-lipocalin muteins and methods for obtaining them |
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| WO2009000006A1 (en) | 2007-06-26 | 2008-12-31 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Display of binding agents |
| EP2167135A2 (en) | 2007-07-12 | 2010-03-31 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| AU2009212747B2 (en) | 2008-01-31 | 2013-11-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| CN102112494A (en) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
| WO2010014622A2 (en) | 2008-07-28 | 2010-02-04 | Fondazione Istituto Firc Di Oncologica Molecolare (Ifom) | In vitro model for modulating the blood brain barrier and methods of screening |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| CN102405230A (en) | 2009-04-22 | 2012-04-04 | 默克专利有限公司 | Antibody fusion proteins with modified fcrn binding sites |
| US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| US8417465B2 (en) | 2009-11-04 | 2013-04-09 | Cfd Research Corporation | Synthetic microfluidic blood-brain barrier |
| EP2534163B1 (en) | 2010-02-09 | 2015-11-04 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| TWI667257B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| JP6109740B2 (en) | 2010-10-29 | 2017-04-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Inflammatory mouse model lacking the N-terminal domain of IL33 |
| JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス，インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
| TWI689314B (en) | 2010-11-30 | 2020-04-01 | 建南德克公司 | Low affinity blood brain barrier receptor antibodies and uses therefor |
| KR20140026372A (en) | 2011-02-02 | 2014-03-05 | 이무노퓨처 아이앤씨. | Drug delivery material capable of passing through blood-brain barrier, and peptide and use thereof |
| US20140112926A1 (en) | 2011-03-16 | 2014-04-24 | Amgen Inc. | Fc VARIANTS |
| CA2832387A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
| CA2828662A1 (en) | 2011-04-20 | 2012-10-26 | Roche Glycart Ag | Method and constructs for the ph dependent passage of the blood-brain-barrier |
| EA201892619A1 (en) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS |
| DK2728002T3 (en) | 2011-06-30 | 2022-04-04 | Chugai Pharmaceutical Co Ltd | HETERODIMERIZED POLYPEPTIDE |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| EP2568051A1 (en) | 2011-09-07 | 2013-03-13 | Stallergenes S.A. | Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy |
| DK177327B1 (en) | 2011-12-23 | 2013-01-14 | Entomopharm Aps | OPTIMIZED INSECT BASED EX VIVO MODEL FOR EXAMINATION OF BLOOD BRAIN BARRIER penetration and method of exposing the insect brain to chemical compounds |
| CN113480639A (en) | 2012-02-09 | 2021-10-08 | 中外制药株式会社 | Fc region variants of antibodies |
| US9475840B2 (en) | 2012-02-27 | 2016-10-25 | Universitat De Barcelona | Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs |
| DK2825553T3 (en) | 2012-03-14 | 2018-09-24 | Regeneron Pharma | : Multispecific antigen binding molecules and applications thereof |
| WO2013138643A1 (en) | 2012-03-16 | 2013-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Soluble engineered monomeric fc |
| CA2871468C (en) | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
| US20150353639A1 (en) | 2012-05-21 | 2015-12-10 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| EP2855520B1 (en) | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
| JP6628966B2 (en) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | Antigen binding molecule containing an altered Fc region |
| US9513280B2 (en) | 2012-08-28 | 2016-12-06 | University Of Utah Research Foundation | Microfluidic biological barrier model and associated method |
| LT2890712T (en) * | 2012-08-29 | 2019-07-25 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
| US10590393B2 (en) | 2012-11-08 | 2020-03-17 | Wisconsin Alumni Research Foundation | Retinoic acid enhanced human stem cell derived blood brain barrier model |
| US9932559B2 (en) | 2012-11-16 | 2018-04-03 | The Johns Hopkins University | Platform for creating an artificial blood brain barrier |
| WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| EP2940135B9 (en) | 2012-12-27 | 2021-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| WO2014144060A1 (en) | 2013-03-15 | 2014-09-18 | Alper Biotech, Llc | Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| EP2978840B1 (en) | 2013-03-26 | 2020-09-30 | Biocant - Centro De Inovação Em Biotecnologia | A human blood-brain barrier model derived from stem cells |
| TWI523945B (en) | 2013-03-29 | 2016-03-01 | Nat Univ Chung Cheng | Establishment of blood - brain barrier model in |
| PL2992010T3 (en) | 2013-04-29 | 2021-08-23 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CN105377942B (en) | 2013-05-14 | 2018-07-31 | 加州理工学院 | Method by delivering therapeutic agent and developer across the nano particle of blood-brain barrier |
| MA38632B1 (en) | 2013-05-20 | 2019-10-31 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| RU2655439C2 (en) | 2013-05-31 | 2018-05-28 | Займворкс Инк. | Heteromultimers with reduced or silenced effector function |
| US20160168253A1 (en) | 2013-08-02 | 2016-06-16 | Hoffmann- La Roche Inc. | Therapeutic fusion protein |
| US9981047B2 (en) | 2013-08-19 | 2018-05-29 | Thomas Lars Andresen | Peptidic nanodelivery composition targeting two receptors |
| EP3041865A2 (en) | 2013-09-03 | 2016-07-13 | NovImmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| SG10202007189VA (en) | 2013-11-21 | 2020-09-29 | Hoffmann La Roche | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
| EP3088518A4 (en) | 2013-12-25 | 2017-09-20 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
| CN111228509A (en) | 2014-01-03 | 2020-06-05 | 豪夫迈·罗氏有限公司 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| CN111057147B (en) | 2014-01-06 | 2023-11-10 | 豪夫迈·罗氏有限公司 | Monovalent blood brain barrier shuttle module |
| US9629801B2 (en) | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
| BR112016016274A2 (en) | 2014-02-19 | 2017-10-03 | Hoffmann La Roche | BLOOD-BRAIN BARRIER BRIDGE |
| WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
| AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
| EP2995949A1 (en) | 2014-09-09 | 2016-03-16 | Institut Pasteur | New in vitro blood brain barrier model |
| EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| CN107250158B (en) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use |
| CN107207609B (en) | 2014-11-20 | 2022-07-19 | 豪夫迈·罗氏有限公司 | Common light chains and methods of use |
| US11820975B2 (en) | 2014-12-09 | 2023-11-21 | National Research Council Of Canada | Human blood brain barrier model |
| WO2016202343A1 (en) | 2015-06-19 | 2016-12-22 | Aalborg Universitet | A triple co-culture model of the blood-brain barrier using primary porcine brain endothelial cells, porcine pericytes and porcine astrocytes |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| PE20221008A1 (en) * | 2015-06-24 | 2022-06-15 | Hoffmann La Roche | ENGINEERED AFFINITY ANTI-TRANSFERRIN RECEPTOR ANTIBODIES |
| WO2016207091A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
| TWI787942B (en) * | 2015-06-24 | 2022-12-21 | 日商Ｊｃｒ製藥股份有限公司 | Anti-human transferrin receptor antibody that passes through blood-brain barrier |
| MX2017017117A (en) | 2015-07-06 | 2018-03-06 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof. |
| WO2017035119A1 (en) | 2015-08-24 | 2017-03-02 | National University Of Singapore | Blood brain barrier model in a 3d co-culture microfluidic system |
| PE20181004A1 (en) | 2015-10-02 | 2018-06-26 | Hoffmann La Roche | BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE |
| AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
| US10233252B2 (en) | 2015-12-21 | 2019-03-19 | Wisconsin Alumni Research Foundation | pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent |
| WO2017134197A1 (en) | 2016-02-05 | 2017-08-10 | Genmab A/S | Multispecific antigen-binding molecule with improved internalization characteristics |
| AR108377A1 (en) | 2016-05-06 | 2018-08-15 | Medimmune Llc | BISPECIFIC UNION PROTEINS AND ITS USES |
| US20200317749A1 (en) | 2016-07-01 | 2020-10-08 | Denali Therapeutics Inc. | Albumin variants for enhanced serum half-life |
| EP3484918A1 (en) | 2016-07-14 | 2019-05-22 | BioArctic Neuroscience AB | Brain delivery protein |
| WO2018031424A1 (en) | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
| EP3556399A1 (en) | 2016-12-19 | 2019-10-23 | Hanmi Pharm. Co., Ltd. | Brain targeting long-acting protein conjugate |
| EA201991577A1 (en) | 2016-12-26 | 2019-12-30 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | NEW ANTIBODIES AGAINST THE HUMAN TRANSFERRIN RECEPTOR, ABLE TO BREAK THE HEMATOENCEPHALIC BARRIER |
| AU2017385274B2 (en) | 2016-12-26 | 2024-02-22 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein including BDNF |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| BR112019017021A2 (en) | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anti-tau antibodies and methods of using them |
| WO2018152326A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
| CA3057619A1 (en) | 2017-03-22 | 2018-09-27 | Research Corporation Technologies, Inc. | Engineered stable ch2 polypeptides |
| WO2018210898A1 (en) | 2017-05-18 | 2018-11-22 | F. Hoffmann-La Roche Ag | Reduction of application-related side reaction of a therapeutic antibody |
| DK3665192T3 (en) | 2017-08-10 | 2023-10-09 | Denali Therapeutics Inc | ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| EP3681909A1 (en) | 2017-09-14 | 2020-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| KR20200058510A (en) | 2017-10-02 | 2020-05-27 | 데날리 테라퓨틱스 인크. | Fusion protein containing enzyme replacement therapy enzyme |
| WO2019089395A1 (en) | 2017-11-02 | 2019-05-09 | Ossianix, Inc. | Improved tfr-selective binding peptides capable of crossing the blood brain barrier |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| BR112020013921A2 (en) | 2018-01-10 | 2020-12-01 | Denali Therapeutics Inc. | transferrin receptor binding polypeptides and uses of these |
| EP3777894A4 (en) | 2018-03-30 | 2022-04-06 | Hanmi Pharm. Co., Ltd. | Brain-targeting, long-acting protein conjugate, preparation method therefor, and composition comprising same |
| CN112424233A (en) | 2018-06-18 | 2021-02-26 | 戴纳立制药公司 | Fusion proteins comprising a progranulin |
| JP7397063B2 (en) | 2018-08-16 | 2023-12-12 | デナリ セラピューティクス インコーポレイテッド | Engineered bispecific proteins |
| AR115998A1 (en) | 2018-08-22 | 2021-03-25 | Denali Therapeutics Inc | ANTI-HER2 POLYPEPTIDES AND METHODS OF USE OF THE SAME |
| US20210395381A1 (en) | 2018-09-14 | 2021-12-23 | Ossianix, Inc. | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers |
| WO2020081575A1 (en) | 2018-10-16 | 2020-04-23 | Denali Therapeutics Inc. | Methods for treating and monitoring progranulin-associated disorders |
| CA3120970A1 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| US20220025065A1 (en) | 2018-12-10 | 2022-01-27 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
| AU2020252554A1 (en) | 2019-04-03 | 2021-10-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| PE20230036A1 (en) | 2019-12-23 | 2023-01-10 | Denali Therapeutics Inc | PROGRANULIN VARIANTS |
| CN115279790A (en) | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | anti-TREM 2 antibodies and methods of use thereof |
| CN115698037A (en) | 2020-02-07 | 2023-02-03 | 戴纳立制药公司 | Methods for treating hunter syndrome |
| JP2023514371A (en) | 2020-02-19 | 2023-04-05 | デナリ セラピューティクス インコーポレイテッド | Engineered anti-HER2 bispecific proteins |
| IL302029A (en) | 2020-10-14 | 2023-06-01 | Denali Therapeutics Inc | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
-
2018
- 2018-02-15 WO PCT/US2018/018371 patent/WO2018152326A1/en unknown
- 2018-02-15 EP EP22199345.4A patent/EP4169937A1/en active Pending
- 2018-02-15 KR KR1020197027034A patent/KR20190129868A/en not_active Application Discontinuation
- 2018-02-15 NZ NZ756763A patent/NZ756763A/en unknown
- 2018-02-15 JP JP2019545273A patent/JP2020508049A/en active Pending
- 2018-02-15 EP EP18708025.4A patent/EP3583120B1/en active Active
- 2018-02-15 CA CA3053375A patent/CA3053375A1/en active Pending
- 2018-02-15 AU AU2018221731A patent/AU2018221731C1/en active Active
- 2018-02-15 PE PE2019001684A patent/PE20191551A1/en unknown
- 2018-02-15 LT LTEPPCT/US2018/018371T patent/LT3583120T/en unknown
- 2018-02-15 HR HRP20221505TT patent/HRP20221505T1/en unknown
- 2018-02-15 MX MX2019009818A patent/MX2019009818A/en unknown
- 2018-02-15 UA UAA201910999A patent/UA127985C2/en unknown
- 2018-02-15 IL IL307373A patent/IL307373A/en unknown
- 2018-02-15 RS RS20221129A patent/RS63818B1/en unknown
- 2018-02-15 ES ES18708025T patent/ES2932759T3/en active Active
- 2018-02-15 BR BR112019016989-0A patent/BR112019016989A2/en unknown
- 2018-02-15 FI FIEP18708025.4T patent/FI3583120T3/en active
- 2018-02-15 CR CR20190372A patent/CR20190372A/en unknown
- 2018-02-15 HU HUE18708025A patent/HUE060983T2/en unknown
- 2018-02-15 PT PT187080254T patent/PT3583120T/en unknown
- 2018-02-15 PL PL18708025.4T patent/PL3583120T3/en unknown
- 2018-02-15 SG SG11201907427YA patent/SG11201907427YA/en unknown
- 2018-02-15 MD MDE20200008T patent/MD3583120T2/en unknown
- 2018-02-15 CN CN201880024350.8A patent/CN110506055A/en active Pending
- 2018-02-15 SI SI201830823T patent/SI3583120T1/en unknown
- 2018-02-15 DK DK18708025.4T patent/DK3583120T3/en active
- 2018-02-15 IL IL268660A patent/IL268660B2/en unknown
- 2018-02-21 TW TW107105816A patent/TWI797106B/en active
-
2019
- 2019-08-14 CL CL2019002307A patent/CL2019002307A1/en unknown
- 2019-08-14 EC ECSENADI201958592A patent/ECSP19058592A/en unknown
- 2019-08-15 CO CONC2019/0008873A patent/CO2019008873A2/en unknown
- 2019-08-16 US US16/543,332 patent/US11795232B2/en active Active
- 2019-08-16 MX MX2023001964A patent/MX2023001964A/en unknown
- 2019-08-16 PH PH12019550147A patent/PH12019550147A1/en unknown
-
2021
- 2021-09-27 AU AU2021240106A patent/AU2021240106B2/en active Active
-
2022
- 2022-08-15 US US17/888,406 patent/US11912778B2/en active Active
-
2023
- 2023-05-02 JP JP2023076265A patent/JP2023100833A/en active Pending
- 2023-09-11 US US18/465,078 patent/US20240018253A1/en active Pending
-
2024
- 2024-01-09 US US18/408,477 patent/US20240141058A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
| SG11201907419PA (en) | Transferrin receptor transgenic models | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201907422RA (en) | Anti-tau antibodies and methods of use thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201901715UA (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201804118VA (en) | Compositions comprising bacterial strains | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof | |
| SG11201810887UA (en) | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof | |
| SG11201809716VA (en) | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201909691WA (en) | Cementitious composite mat | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof |